据有关数据表明,今年以来,上海医药(集团)总公司各企业努力克服当前生产经营面临的各种困难和矛盾,在宏观不宽松的环境下负重前进,取得了上半年生产经营发展速度和效益“双过半”的丰硕成果。今年1～6月,总公司完成工业总产值62.5亿元,同比增长22.5％,完成年度计划的50.3％;实现利润1.2亿元,同比增长4.95％,完成年度计划的60％;速度、效益同向增长,为今年全年医药经济工作任务完成打下了扎 According to relevant data, since the beginning of this year, all companies of the Shanghai Pharmaceutical (Group) Corporation have made efforts to overcome various difficulties and contradictions faced by the current production and operation, and carried forward in a macro-indifferent environment, achieving a speed and efficiency in the production and operation of the first half of the year. “Both more than half” fruitful results. From January to June this year, the head office completed a total industrial output value of 6.25 billion yuan, a year-on-year increase of 22.5%, 50.3% of the annual plan, and a profit of 120 million yuan, a year-on-year increase of 4.95%, completing 60% of the annual plan; The growth has laid a foundation for the completion of the medical economic work task this year.